Latest Health News

Wesfarmers has announced the wind down of Catch as a standalone business, transferring its e-commerce fulfilment centres to Kmart Group and integrating key digital capabilities into its retail divisions to strengthen omnichannel offerings.

Korvest Ltd has announced a fully franked ordinary dividend of AUD 0.25 per share for the six months ending December 2024, signaling steady shareholder returns.

Immuron Limited reports a striking 70% quarter-on-quarter increase in Travelan® sales, driven by expanded pharmacy distribution in Australia and North America.

Visioneering Technologies reports promising interim results from its PROTECT trial, showing significant control of myopia progression in children using NaturalVue® Multifocal lenses.

Pro Medicus has secured a $33 million, nine-year contract to implement its Visage 7 cloud-based imaging platform across the University of Kentucky’s health system, marking a significant expansion in North American academic healthcare.

Memphasys Limited has secured a major scientific endorsement for its RoXsta™ antioxidant profiling system, positioning the technology for expanded clinical and agricultural applications.

Genesis Minerals Limited reported a record December quarter gold production of 57,055oz, driven by an accelerated Laverton mill restart and strong operational execution. The company’s cash reserves surged 34% to A$238 million, underpinning its debt-free growth strategy.

Orthocell Limited has reported a third consecutive quarter of record revenue, driven by strong sales growth and strategic market expansions, including a key US FDA submission for its nerve repair product Remplir™.

Anatara Lifesciences has successfully completed recruitment for the second stage of its pivotal GaRP-IBS clinical trial, with headline results expected in Q1 2025. The company also launched a new anti-obesity project and strengthened its cash position through recent capital raises.

HITIQ Limited has received $1.6 million from the R&D Tax Incentive Scheme, using most of it to repay its RDTI Facility with Keystone Capital Partners, signaling a strategic move to streamline its R&D funding.

Immuron has submitted its Phase 2 clinical study report for Travelan® to the FDA, revealing statistically significant immunological and microbiome benefits. The company is preparing to engage the FDA for Phase 3 trial discussions while progressing a large field study with military personnel.

Way 2 Vat Ltd's trading suspension is scheduled to end on 13 January 2025, coinciding with the announcement of a proposed capital raising that could reshape its financial outlook.